Grilled Cheese

ExploreLog inSign up
Terms of UsePrivacy PolicyCommunity StandardsHelpGet the app

Grilled Cheese is a product of Village Compute

Version devBuilt at: 2026-10-10 01:38:52 EDT

Explore

PostsPeople
LatestRanked
@tamedoncol.bsky.socialOct 8, 2026, 7:00 AM

Get ready for #ESMO26 by revisiting the evolving treatment landscape of #SCLC with this review published on #TAMO in 2025.
From current standards to DLL3-targeted therapies, #ADCs and emerging biomarkers.
#Lungcancer
๐Ÿ”— buff.ly/B2U9VpQ
@Roya_Behrouzi @fblackhall

@toxy4ny.bsky.socialOct 5, 2026, 3:26 PM

Monday's redteam toolkit - Even more privileged ADCS ESC_CES

Web Enrollment and CES both perform certificate enrollment, but they are completely different HTTP protocols.

github.com/ADHDMurky/AD... #redteam #tool #ADCS #AD #fresh #attack #CES #tools #ESC_CES #critical #education

@onc-rg.bsky.socialOct 2, 2026, 12:07 AM

๐™๐™๐™š 2026 ๐™€๐™Ž๐™ˆ๐™Š ๐™‡๐˜ฝ๐˜ผ ๐™‡๐™–๐™ฃ๐™™๐™จ๐™˜๐™–๐™ฅ๐™š: ๐™‘๐™ž๐™จ๐™ช๐™–๐™ก๐™ž๐™ฏ๐™š๐™™.
Which mechanisms are commanding the late-breaker spotlight this year?

#ESMO2026 #ESMO26 #Oncology #NSCLC #SCLC #ADCs #vaccines #ClinicalData #DrugTrials #CompetitiveStrategy

Our analysts crunched the numbers across all LBAs: โœ”๏ธADCs lead the field โ€” nearly a third of all LBA drugs, spanning NSCLC, breast, ovarian, and beyond โœ”๏ธCheckpoint inhibition isn't just a category โ€” it's still the default combo partner, showing up alongside ADCs, vaccines, PARP inhibitors and more โœ”๏ธBeyond PD-(L)1 and the usual ADC targets (HER2, TROP-2, B7-H3), RAS/KRAS momentum is continuing from ASCO Stay ahead of the competitive curve with verified insights. Our analysts crunched the numbers across all LBAs: โœ”๏ธADCs lead the field โ€” nearly a third of all LBA drugs, spanning NSCLC, breast, ovarian, and beyond โœ”๏ธCheckpoint inhibition isn't just a category โ€” it's still the default combo partner, showing up alongside ADCs, vaccines, PARP inhibitors and more โœ”๏ธBeyond PD-(L)1 and the usual ADC targets (HER2, TROP-2, B7-H3), RAS/KRAS momentum is continuing from ASCO Stay ahead of the competitive curve with verified insights.
@pharmaphorum.bsky.socialSep 28, 2026, 11:35 AM

#MSD and #DaiichiSankyo's regulatory efforts for their antibody-drug conjugates (#ADCs) for cancer have stuttered again, with a withdrawn filing for #lungcancer candidate ifinatamab deruxtecan (I-DXd) in the US.

pharmaphorum.com/news/msd-dai...

@newsen.bsky.socialSep 24, 2026, 2:31 PM

Innovative Collaboration Between Sanyou Bio and NovoCodex to Develop Dual-Payload ADCs #China #Shanghai #Sanyou_Bio #ADCs #NovoCodex

@antibodytx.bsky.socialSep 23, 2026, 1:36 PM

Antibody Therapeutics (IF=4.8, Oxford University Press) โšก Review Highlight -Overview of antibody-drug conjugates nonclinical and clinical toxicities and related contributing factors.
doi.org/10.1093/abt/...
#adc #antibodydrugconjugate #adcs #antibodydrugconjugates #toxicity

@antibodytx.bsky.socialSep 18, 2026, 2:03 PM

Antibody Therapeutics (IF=4.8, Oxford University Press) โšก Review Highlight -The evolving landscape of enzymatic technologies for precision synthesis of antibodyโ€“drug conjugates.
doi.org/10.1093/abt/...
#antibodydrugconjugate #adcs #antibodydrugconjugates #adpribosylcyclase #cd38

@medchemexpress.bsky.socialSep 14, 2026, 12:04 PM

๐Ÿ’Š #WCLC 2026 | Key Advances in #LungCancer Research
From B7-H3 ADCs to next-generation TKIs and combination strategies, WCLC 2026 highlights evolving approaches in #NSCLC and #SCLC:
๐Ÿ”—https://bit.ly/4xW10sT

#WCLC2026 #B7H3 #ADCs #TKI #CancerResearch

@drjkyl.bsky.socialSep 11, 2026, 9:22 PM

Antibody-drug conjugates and beyond in platinum-resistant ovarian cancer: A comprehensive review of emergent strategies

@tamedoncol.bsky.social
@journals.sagepub.com

journals.sagepub.com/doi/10.1177/...

#ADCs #cancerresistance #targetedtherapy #oncology #openaccess